Studiedetails

Type carcinoma: NSCLC met mutatie
Stadium: Stage IIIB or IIIC disease who is not a candidate for surgical resection or definitive chemoradiation, or Stage IV non-squamous NSCLC disease
Mutatie: n/a
Lijn: 1ste
Site: Erasmus MC & Amphia
Contactgegevens:

long.oncologie@erasmusmc.nl
researchlongoncologie@amphia.nl
Website:

 Inclusiecriteria

– Has Stage IIIB or IIIC disease who is not a candidate for surgical resection or definitive chemoradiation, or Stage IV non-squamous NSCLC disease
– Has not been treated with systemic anticancer therapy for advanced or metastatic non-squamous NSCLC. Subjects who received adjuvant or neoadjuvant therapy other than those listed in the exclusion criteria are eligible if the adjuvant/ neoadjuvant therapy was completed at least 6 months prior to the diagnosis of advanced/ metastatic disease
– Has tumor with PD-L1 TPS <50%
– Has documented negative test results for EGFR, ALK, and ROS1 actionable genomic alterations (AGAs)
– ECOG performance status of 0 or 1

 Exclusiecriteria

Meer studies

Een overzicht van alle lopende studies binnen het longkankernetwerk. Filter op type mutatie:

KontRASt-06

An open-label Phase II trial evaluating the activity and safety of JDQ443 single-agent as first-line treatment for patients with locally advanced or metastatic KRAS G12C-mutant non-small cell lung cancer (NSCLC) with a PD-L1 expression <1% or a PD-L1 expression ≥1% and an STK11 co-mutation